Compare General Motors Company (GM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Merck & Co., Inc. — how do they compare? General Motors Company trades at $88.82 (market cap $78.40B), while Merck & Co., Inc. trades at $129.69 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 4.1× General Motors Company's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| GM | MRK | |
|---|---|---|
Market Cap | $78.40B | $321.77B |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $131.84 |
52-Week Low | $54.16 | $77.60 |
Enterprise Value | $181.38B | $368.53B |
Dividend Yield | 0.81% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $87.96, up 0.43% with a bullish technical signal and strong analyst support. The company shows robust cash flow generation ($26.87B operating cash flow in 2025) and has beaten earnings estimates for three consecutive quarters. Recent developments include a $4.5B parts supply deal and a renewed 20-year joint venture in China, positioning GM for supply chain stability and international growth.
GM presents a compelling investment case with 65% analyst buy ratings and a $108.82 consensus price target offering 24% upside. However, declining profit margins (1.05% net margin in 2025) and rising debt levels (46.79% debt-to-asset ratio) warrant caution. The stock's valuation appears reasonable with P/S of 0.45 and P/B of 1.26, but investors should monitor execution on EV strategy transitions and macroeconomic pressures on auto demand.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
